Targeted Cancer Therapies and the Fight to Make Treatment Less Fearful featuring Stanley Lewis

In this episode of The Connect Current, we sit down with Stanley Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to explore how targeted cancer therapies can create better options for patients facing difficult diseases. Stanley shares the story behind A28’s targeted oncolytic peptide platform, the company’s lead candidate AT-101, and what it takes to move a clinical-stage biopharmaceutical company from scientific promise toward real-world impact. The conversation dives into patient need, treatment burden, clinical development, capital, partnerships, and why A28’s next chapter as one of Connect’s 2026 Cool Companies reflects the strength of San Diego’s growing life sciences ecosystem.Recorded at UC San Diego Park & Market:https://parkandmarket.ucsd.edu/Learn more about A28 Therapeutics:https://www.a28tx.com/